Genmab A/S (NASDAQ:GMAB – Get Free Report) and Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.
Insider & Institutional Ownership
7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations for Genmab A/S and Bolt Biotherapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genmab A/S | 0 | 1 | 10 | 1 | 3.00 |
| Bolt Biotherapeutics | 1 | 1 | 2 | 0 | 2.25 |
Genmab A/S currently has a consensus price target of $53.61, suggesting a potential upside of 5.34%. Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 141.06%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Genmab A/S.
Valuation and Earnings
This table compares Genmab A/S and Bolt Biotherapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genmab A/S | $3.72 billion | 8.54 | $963.00 million | $1.17 | 43.50 |
| Bolt Biotherapeutics | $4.70 million | 2.46 | -$33.38 million | ($16.44) | -0.37 |
Genmab A/S has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Genmab A/S and Bolt Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genmab A/S | 16.97% | 13.67% | 6.42% |
| Bolt Biotherapeutics | -611.47% | -126.23% | -54.70% |
Risk and Volatility
Genmab A/S has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
Summary
Genmab A/S beats Bolt Biotherapeutics on 11 of the 15 factors compared between the two stocks.
About Genmab A/S
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
